sdbn.org

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy
Posted by sandiegobiotech February 3rd, 2012 .
No Comments

—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Angry at the Genome
Posted by sandiegobiotech January 24th, 2012 .
No Comments

In 2004, I was an enthusiastic postdoctoral researcher in Eric Lander’s lab at the Broad Institute, with the job I had dreamed of since I was 10 years old. Growing up in Paducah, KY, I read Isaac...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Angry at the Genome
Posted by sandiegobiotech January 24th, 2012 .
No Comments

In 2004, I was an enthusiastic postdoctoral researcher in Eric Lander’s lab at the Broad Institute, with the job I had dreamed of since I was 10 years old. Growing up in Paducah, KY, I read Isaac...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

In Life Sciences Partnerships, You Must be Smart from the Beginning
Posted by sandiegobiotech January 20th, 2012 .
No Comments

As early stage biotech startups advance their drug candidates into pre-clinical development, many must decide at some point whether to start working with a big pharmaceutical or biotech partner to...

[[Click headline to continue reading.]] More...

Drug Development, Drug Discovery, News, Syndication, Xconomy »

A Sweet Deal: How Amira Reinvented Itself as a Drug Discovery Engine
Posted by sandiegobiotech December 23rd, 2011 .
No Comments

The sale of Amira Pharmaceuticals will likely go down as one of the standout life sciences deals of 2011—it certainly ranks as one of the biggest payouts in San Diego, where Amira was founded in...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

The Move to Value-Based Pricing for Prescription Drugs
Posted by sandiegobiotech December 20th, 2011 .
No Comments

The standard marketing value equation taught in business school states value equals utility or benefits less costs. Because the relationship between the price of medicines and the value they deliver...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

SF’s Prescience Sharpens New Biotech Business Model in San Diego
Posted by sandiegobiotech December 9th, 2011 .
No Comments

[Updated 12/12/11 11:20 am to clarify terms for startups. See below.] After spending much of her career in the tech sector, Melinda Richter has been pondering a provocative question for the life...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Lpath Looks to Raise $10 Million Through Secondary Offering
Posted by sandiegobiotech December 8th, 2011 .
No Comments

San Diego’s Lpath (OTC: LPTN), a biotech developing specialized monoclonal antibodies for cancer and other diseases, intends to raise about $10 million through a secondary offering of stock and...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Fresh Off Amira Success, Versant’s Bolzon and San Diego’s Prasit Begin Anew with Inception
Posted by sandiegobiotech November 29th, 2011 .
No Comments

Last year’s blockbuster film “Inception,” was about a dream within a dream within a dream, which made it a little hard to follow. Likewise with “Inception,” the San Diego life sciences startup that...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Xconomists of the Week: Tom Maniatis and Marc Tessier-Lavigne Lead the Charge on the New York Genome Center
Posted by sandiegobiotech November 3rd, 2011 .
No Comments

Today marked the official launch of the New York Genome Center, a collaboration among 11 top academic institutions that’s designed to accelerate genomic research. The initiative—supported...

[[Click headline to continue reading.]] More...